Songnian Lin

This inventor holds 30 USPTO granted patents and 24 published patent applications, plus 2 CIPO patents and 15 EPO patents, primarily in Diabetes Treatment. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc., Other. Active years: 2008-2025.

USPTO Granted Patents = 30 (Patent Applications = 24)

% Patents Active = 96.7

CIPO Patents = 2 (Patent Applications = 6)

EPO Patents = 15 (Patent Applications = 34)

Average Co-Inventor Count = 5.1

ph-index = 4

Forward Citations = 37(Granted Patents)

Location History:

Monroe, NJ (US) (2008 - 2018)
Holmdel, NJ (US) (2016 - 2023)

Company Filing History:

28 out of 2,405

Merck Sharp + Dohme Corp.

1 out of 834,411

Other

patents

Years Active: 2008-2025

Loading Chart...

Areas of Expertise:

Glucose-Responsive Insulin

Insulin Conjugates

Glucagon Receptor Antagonists

Tyrosine-Specific Insulin

Controlled Insulin Delivery

Interleukin-2 Conjugates

Antidiabetic Compounds

Isoquinoline Derivatives

GLP-1 Analogues

Cholesterol Absorption Inhibitor

Dimer-Incretin Conjugates

Tricyclic Compounds

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12427187 - Glucose-responsive insulin conjugates (2025-09-30),

2. 11827684 - Human interleukin-2 conjugates biased for the interleukin-2 receptor beta GAMMAc dimer and conjugated to a nonpeptidic, water-soluble polymer (2023-11-28),

3. 11820805 - Conjugate based systems for controlled insulin delivery (2023-11-21),

4. 11530250 - Tyrosine-specific functionalized insulin and insulin analogs (2022-12-20),

5. 11413352 - Conjugate based systems for controlled insulin delivery (2022-08-16),

6. 11077092 - Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor (2021-08-03),

7. 11058775 - Insulin dimer-incretin conjugates (2021-07-13),

8. 11041009 - Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes (2021-06-22),

9. 10953076 - Insulin receptor partial agonists and GLP-1 analogues (2021-03-23),

10. 10800827 - Insulin receptor partial agonists (2020-10-13),

11. 10689430 - Insulin receptor partial agonists (2020-06-23),

12. 10183981 - Insulin receptor partial agonists (2019-01-22),

13. 10065945 - Isoquinoline derivatives as MGAT2 inhibitors (2018-09-04),

14. 10017556 - Insulin receptor partial agonists (2018-07-10),

15. 9889205 - Glucose-responsive insulin conjugates (2018-02-13),

Title: The Innovative Journey of Songnian Lin

Introduction: Songnian Lin, a pioneering inventor based in Holmdel, NJ (US), has made significant contributions to the field of technology with his groundbreaking inventions and patents.

Latest Patents: Songnian Lin holds several patents in the realm of telecommunications and networking technologies, showcasing his continuous dedication to innovation in the industry.

Career Highlights: With a career spanning over two decades, Songnian Lin has worked tirelessly to push the boundaries of technological advancements. His expertise in developing cutting-edge solutions has earned him recognition as a leading figure in the field.

Collaborations: Throughout his career, Songnian Lin has collaborated with top research institutions, universities, and tech companies to further his inventions and bring them to life. His collaborative efforts have led to the creation of revolutionary products that have shaped the industry.

Conclusion: Songnian Lin's passion for innovation and his relentless pursuit of excellence have solidified his position as a trailblazing inventor in the technology sector. His work continues to inspire future generations of inventors to push the boundaries of what is possible in the world of technology.